Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in MRD-positive B-precursor ALL
NCT01207388Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2010
- Primary completion
- Feb 2014
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Started Nov 2010; status: completed.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT01207388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207388.